HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 6 (2009), Issue 12 (December)

1. Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.
   Pediatrics, 124(6): e1189-97. [Abstract] [Full-text]
2. An excess of rare genetic variation in ABCE1 among Yorubans and African-American individuals with HIV-1.
   Genes Immun, 10(8): 715-21. [Abstract] [Full-text]
3. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
   J Med Chem, 52(23): 7604-17. [Abstract] [Full-text]
4. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
   N Engl J Med, 361(23): 2230-40. [Abstract] [Full-text]
5. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
   N Engl J Med, 361(23): 2209-20. [Abstract] [Full-text]
6. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects.
   J Med Chem, 52(23): 7778-87. [Abstract] [Full-text]
7. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors.
   J Med Chem, 52(23): 7631-9. [Abstract] [Full-text]
8. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
   J Med Chem, 52(23): 7689-705. [Abstract] [Full-text]
9. Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
   J Med Chem, 52(23): 7473-87. [Abstract] [Full-text]
10. Betulinic acid derivatives as human immunodeficiency virus type 2 (HIV-2) inhibitors.
    J Med Chem, 52(23): 7887-91. [Abstract] [Full-text]
11. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
    Virology, 396(2): 339-48. [Abstract] [Full-text]
12. Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection.
    Virology, 396(2): 246-55. [Abstract] [Full-text]
13. Adaptive changes in HIV-1 subtype C proteins during early infection are driven by changes in HLA-associated immune pressure.
    Virology, 396(2): 213-25. [Abstract] [Full-text]
14. Direct relationship between virus load and systemic immune activation in HIV-2 infection.
    J Infect Dis, 201(1): 114-22. [Abstract] [Full-text]
15. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.
    J Infect Dis, 201(1): 132-41. [Abstract] [Full-text]
16. Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.
    J Biol Chem, 284(51): 35681-91. [Abstract] [Full-text]
17. Formation of the tRNALys packaging complex in HIV-1.
    FEBS Lett, 584(2): 359-65. [Abstract] [Full-text]
18. The requirement for cellular transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase.
    J Virol, 84(1): 397-406. [Abstract] [Full-text]
19. Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.
    J Virol, 84(1): 340-51. [Abstract] [Full-text]
20. Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.
    J Virol, 84(1): 201-9. [Abstract] [Full-text]
21. The range of human APOBEC3H sensitivity to lentiviral Vif proteins.
    J Virol, 84(1): 88-95. [Abstract] [Full-text]
22. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate.
    J Virol, 84(1): 492-502. [Abstract] [Full-text]
23. Differential modulation of CCR5-tropic human immunodeficiency virus-1 transfer from macrophages towards T cells under interleukin-4/interleukin-13 microenvironment.
    Hum Immunol, 71(1): 1-13. [Abstract] [Full-text]
24. Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES.
    Proteins, 78(2): 295-308. [Abstract] [Full-text]
25. Relevance of CD38 expression on CD8 T cells to evaluate antiretroviral therapy response in HIV-1-infected youths.
    Scand J Immunol, 71(1): 45-51. [Abstract] [Full-text]
26. Functions of Tat: the versatile protein of human immunodeficiency virus type 1.
    J Gen Virol, 91: 1-12. [Abstract] [Full-text]
27. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
    J Gen Virol, 91: 250-8. [Abstract] [Full-text]
28. HLA-C is necessary for optimal human immunodeficiency virus type 1 infection of human peripheral blood CD4 lymphocytes.
    J Gen Virol, 91: 235-41. [Abstract] [Full-text]
29. HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses.
    J Exp Med, 206(13): 2959-66. [Abstract] [Full-text]
30. A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.
    J Immunol, 184(1): 359-68. [Abstract] [Full-text]
31. HIV infection is associated with a preferential decline in less-differentiated CD56dim CD16+ NK cells.
    J Virol, 84(2): 1183-8. [Abstract] [Full-text]
32. Beauvericin and enniatins H, I and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase.
    J Antibiot (Tokyo), 62(12): 687-90. [Abstract] [Full-text]
33. Analysis of the viral elements required in the nuclear import of HIV-1 DNA.
    J Virol, 84(2): 729-39. [Abstract] [Full-text]
34. A single amino acid substitution in HIV-1 reverse transcriptase significantly reduces virion release.
    J Virol, 84(2): 976-82. [Abstract] [Full-text]
35. Implication of serine residues 271, 273, and 275 in the human immunodeficiency virus type 1 cofactor activity of lens epithelium-derived growth factor/p75.
    J Virol, 84(2): 740-52. [Abstract] [Full-text]
36. The immune response during acute HIV-1 infection: clues for vaccine development.
    Nat Rev Immunol, 10(1): 11-23. [Abstract] [Full-text]
37. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.
    J Acquir Immune Defic Syndr, 53(1): 86-94. [Abstract] [Full-text]
38. Mortality associated with discordant responses to antiretroviral therapy in resource-constrained settings.
    J Acquir Immune Defic Syndr, 53(1): 70-7. [Abstract] [Full-text]
39. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy.
    J Infect Dis, 201(2): 293-6. [Abstract] [Full-text]
40. The use of glutaraldehyde-fixed chicken red blood cells as counting beads for performing affordable single-platform CD4(+) T-lymphocyte count in HIV-1-infected patients.
    J Acquir Immune Defic Syndr, 53(1): 47-54. [Abstract] [Full-text]
41. Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption.
    J Acquir Immune Defic Syndr, 53(1): 36-46. [Abstract] [Full-text]
42. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi.
    J Acquir Immune Defic Syndr, 53(1): 6-13. [Abstract] [Full-text]
43. Hospitalization and mortality among primarily nonbreastfed children during a large outbreak of diarrhea and malnutrition in Botswana, 2006.
    J Acquir Immune Defic Syndr, 53(1): 14-9. [Abstract] [Full-text]
44. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun.
    J Acquir Immune Defic Syndr, 53(1): 107-10. [Abstract] [Full-text]
45. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era.
    J Acquir Immune Defic Syndr, 53(1): 102-6. [Abstract] [Full-text]

© 2004-2010 HIV Research Today. All Rights Reserved.